Modifying humidity and convection to glabrous tissue to control metabolism
Systems and methods for affecting metabolism, such as the treatment of metabolic syndrome are disclosed. A method for treating metabolic syndrome can include one or more of the steps including identifying a region of the patient comprising glabrous tissue; positioning the region of the patient comprising glabrous tissue into an enclosed chamber; adjusting the relative humidity of the enclosed chamber sufficient to create a physiologic metabolic effect; and activating a convection fan within the chamber to promote heat transfer from the glabrous tissue. The method need not involve altering the temperature within the enclosed chamber.
1. A system for modulating glabrous tissue of a patient, comprising:
a housing surrounding a chamber;
a compressor configured to supply de-humidified air to the chamber sufficient to transfer heat away from the glabrous tissue, the de-humidified air having a relative humidity of less than about 30%;
an inlet fluidly connecting the compressor to the chamber;
a patient port operably connected to the chamber and configured to house an extremity of the patient comprising the glabrous tissue, the patient port comprising a seal such that upon insertion of the extremity of the patient into the chamber a seal is formed in an interior of the chamber;
a power source;
a gas outlet fluidly connected to the chamber; and
a fan configured to flow air to the glabrous tissue; and
a controller configured to adjust the relative humidity of the de-humidified air into the chamber,
wherein the system is not configured to alter a temperature or pressure of the interior of the chamber.
2. The system of claim 1 , wherein the controller is configured to adjust the relative humidity based upon receiving information from a sensor conveying physiologic information about the patient.
3. The system of claim 1 , further comprising at least one humidity sensor within the chamber.
4. The system of claim 1 , wherein the compressor comprises an oxygenator.
5. The system of claim 1 , wherein the system is at least partially in the shape of a shoe configured to be worn by the patient to treat plantar glabrous tissue of the patient.
6. The system of claim 1 , wherein the system is at least partially in the shape of a glove configured to be worn by the patient to treat palmar glabrous tissue of the patient.
7. A method for treating a patient, comprising:
inserting a region of the patient comprising glabrous tissue into an enclosed chamber; and
applying a gas having a preselected first relative humidity selectively to the region of the patient comprising glabrous tissue within the enclosed chamber such that the region of the patient comprising glabrous tissue does not contact a sidewall of the chamber, wherein the first relative humidity is less than about 30%,
wherein air surrounding the patient outside of the enclosed chamber has a second relative humidity, wherein the second relative humidity is greater than the first relative humidity, and
wherein the method does not alter a temperature or pressure of an environment surrounding the region of the patient within the enclosed chamber.
8. The method of claim 7 , further comprising activating a fan configured to promote heat loss from the glabrous tissue.
9. The method of claim 7 , wherein the first relative humidity is less than about 25%.
10. The method of claim 7 , wherein the first relative humidity is less than about 20%.
11. The method of claim 7 , wherein the first relative humidity is less than about 15%.
12. The method of claim 7 , wherein the method is sufficient to increase a basal metabolic rate of a patient by at least 5% in a 24 hour period following the treatment.
13. The method of claim 7 , wherein the method is sufficient to increase a basal metabolic rate of a patient by at least 10% in a 24 hour period following the treatment.
14. The method of claim 7 , wherein applying the gas is sufficient to reduce a core temperature of the patient following the treatment.
15. The method of claim 7 , wherein applying the gas is sufficient to increase adiponectin production in the patient a week following the treatment.
16. The method of claim 7 , for the treatment of weight loss.
17. The method of claim 7 , for the treatment of one or more of the following selected from the group consisting of: diabetes mellitus, dyslipidemia, metabolic syndrome, and hypertension.
18. The method of claim 7 , wherein the method does not comprise modifying a temperature within the enclosed chamber.
19. The method of claim 7 , wherein applying the gas is done continuously for at least about 30 minutes.
20. The method of claim 7 , wherein applying the gas is done continuously for at least about 60 minutes.